secwatch.observer — SEC 8-K summary
======================================

Issuer:     Intellia Therapeutics, Inc. (NTLA)
CIK:        0001652130
Form:       8-K
Filed at:   2026-02-26T23:59:59+00:00
Accession:  0001193125-26-073456
Event type: earnings
Sentiment:  neutral
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Intellia Q4 net loss $95.8M; lonvo-z Phase 3 data mid-2026; nex-z clinical hold remains for ATTR-CM
--------------------------------------------------------------------------------

- Q4 2025 net loss $95.8M vs $128.9M Q4 2024; cash $605.1M, expected to fund operations into H2 2027.
- Lonvo-z (HAE): HAELO Phase 3 topline data by mid-2026; BLA submission H2 2026; U.S. launch anticipated H1 2027.
- Nex-z (ATTR): MAGNITUDE-2 enrollment restart underway, completion expected H2 2026; MAGNITUDE clinical hold on ATTR-CM unresolved.
- Market research: 99% of HAE patients likely to take lonvo-z; 92% of physicians would prescribe.
- R&D expenses $88.7M (down from $116.9M); collaboration revenue $23.0M (up from $12.9M) including $9.0M from SparingVision termination.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1652130/000119312526073456/0001193125-26-073456-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1652130/000119312526073456/ntla-20260226.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-073456

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer